Navigation Links
EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
Date:3/21/2013

h a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.  EntreMed, Inc. recently initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
3. EntreMed Reports Second Quarter 2012 Financial Results
4. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
7. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
10. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
11. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... is a hollow needle commonly used with a syringe ... extract fluids from it. A hypodermic needle is used ... that cannot be ingested. Hypodermic needles are broadly classified ...
(Date:7/11/2014)... -- On Thursday, July 10, 2014, ... Jones Industrial Average finished the day 0.42% lower at 16,915.07, ... losses were broad based as eight out of ten sectors ... Sector Index ended the day at 711.88, down 0.02%, while ... Investor-Edge has initiated coverage on the following equities: Covidien PLC ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... OAK BROOK, Ill. , July 12 The University ... agreement to Ascent, a leader in health care resource sustainability. The agreement, ... 1, 2010 . Under the contract, Ascent will offer single-use device (SUD) ... , , , ...
... July 12 ( http://www.myprgenie.com ) -- Medrium, Inc., one ... announced it has signed a partnership agreement with RelayHealth to use ... LabCorp and to provide LabCorp results to physicians utilizing the Medrium ... , ...
Cached Medicine Technology:University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 2University HealthSystem Consortium Awards Single-Source Agreement to Ascent for Medical Device Reprocessing Services 3Medrium Partners With RelayHealth 2Medrium Partners With RelayHealth 3
(Date:7/13/2014)... editorial published today in The Lancet Neurology ... consideration the long term neurological problems that repeated ... most common form of sports-related traumatic brain injury ... may include dementia, amyotrophic lateral sclerosis, and other ... is perhaps more concerning, is that even when ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway ... opening up potential new therapeutic strategies for an ... is a chronic inflammatory disorder of the esophagus. ... certain foods and an over-accumulation in the esophagus ... the body,s immune system). EoE can cause a ...
(Date:7/13/2014)... July 13, 2014 The North American water ... in 2013 to $5,450 million by 2018, at a CAGR ... market is expanding at a rapid pace in North America. ... tightening laws on water & wastewater storage and collection, and ... The market is expanding at a healthy rate in Canada, ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... Programs for Eating Disorders,( http://www.remudaranch.com ), the nation,s ... surround the nation,s obsession,with dieting. As the dieting ... Americans continue to lose and gain weight in ... cycling may elevate blood pressure,reduce good cholesterol, deplete ...
... Medical Technologies,Inc., an innovator of endovascular treatments for ... another patent for its,Pathway PV(TM) Atherectomy System. The ... related to Pathway Medical,s innovative,atherectomy system, which is ... the legs. Pathway Medical has a total of ...
... women to enjoy casual sex just as men always had. ... the UK, the negative feelings reported by women after one-night ... sexual encounters. Her findings (1) are published online in ... , Men are more likely to reproduce and therefore to ...
... hurt. It was like [their father] had met some gal ... she wanted all his money. I felt they didn,t give ... still hurts.", --Remarried wife of 12 years, caring for husband ... Mich.---Late-life remarriage complicates caring for an ailing spouse, according to ...
... June 25 Hologic, Inc.,(Nasdaq: HOLX ) today ... the waiting period under the Hart-Scott-Rodino,Antitrust Improvements Act of ... in connection with Hologic,s previously announced tender offer for,all ... Third Wave,Technologies, Inc. (Nasdaq: TWTI ). The early ...
... looking for qualified candidates and tens of thousands of jobs being created ... graduates and despite the layoff announcements that tend to shock the average ... ... number of available jobs in health care continued to rise through the ...
Cached Medicine News:Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 2Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 3Health News:Was it good for you too? 2Health News:Late-life remarriage: Stepfamilies make caring more complex 2Health News:Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 3
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... The Retinal Acuity Meter (RAM) is the ... to accurately predict RETINAL ACUITY in eyes with ... hand-held, battery operated, and can test each eye ... Optics, Inc. and tested at Columbia University in ...
... The Hoffmann® II Hybrid External Fixation ... next generation in hybrid fixation. It ... surgeons and is designed to offer ... exclusive patented Hoffmann® snap-fit technology. , ...
... add individual components for individual indications. XCaliber ... Made of an innovative composite plastic material, ... much lighter. This means it's easier to ... for the patient. ,Come pre-assembled, packaged sterile, ...
Medicine Products: